Status: Not yet recruiting
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
This Phase II open-label interventional clinical trial aims to evaluate the efficacy of romiplostim, in patients with severe aplastic anemia (SAA), both treatment naïve and relapsed/refractory, in inducing trilineage hematopoiesis in children and young adults.
Participants needed: 15
Trial details
Phase: Phase 2Age: 2-21Biological sex: AllType: InterventionalSponsor: Anjali SharathkumarUpdated: Dec 19, 2025Locations: 1
Eligibility criteria
Age ≥2 years to ≤21 years [+5]
Age < 2 years or >21 years *Availability of suitable HLA-matched related or HLA-... [+21]